Dipeptidyl-Peptidase IV Inhibitors

"Dipeptidyl-Peptidase IV Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release.

Descriptor ID	D054873
MeSH Number(s)	D27.505.519.389.745.335 D27.505.696.422.500
Concept/Terms	Dipeptidyl-Peptidase IV Inhibitors Dipeptidyl-Peptidase IV Inhibitors Dipeptidyl Peptidase IV Inhibitors Inhibitors, Dipeptidyl-Peptidase IV Gliptins Dipeptidyl-Peptidase 4 Inhibitors Dipeptidyl Peptidase 4 Inhibitors

Below are MeSH descriptors whose meaning is more general than "Dipeptidyl-Peptidase IV Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Protease Inhibitors [D27.505.519.389.745]
Dipeptidyl-Peptidase IV Inhibitors [D27.505.519.389.745.335]
Physiological Effects of Drugs [D27.505.696]
Hypoglycemic Agents [D27.505.696.422]
Dipeptidyl-Peptidase IV Inhibitors [D27.505.696.422.500]

Below are MeSH descriptors whose meaning is related to "Dipeptidyl-Peptidase IV Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Dipeptidyl-Peptidase IV Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Dipeptidyl-Peptidase IV Inhibitors" by people in this website by year, and whether "Dipeptidyl-Peptidase IV Inhibitors" was a major or minor topic of these publications.

Bar chart showing 10 publications over 7 distinct years, with a maximum of 2 publications in 2014 and 2015 and 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2007	0	1	1
2014	0	2	2
2015	0	2	2
2017	1	1	2
2020	1	0	1
2023	1	0	1
2024	1	0	1

Below are the most recent publications written about "Dipeptidyl-Peptidase IV Inhibitors" by people in Profiles.

Lin TY, Kang EY, Shao SC, Lai EC, Wang NK, Garg SJ, Chen KJ, Kang JH, Wu WC, Lai CC, Hwang YS. Association of sodium-glucose cotransporter-2 inhibitors and the risk of retinal vascular occlusion: A real-world retrospective cohort study in Taiwan. Diabetes Metab Res Rev. 2024 02; 40(2):e3773.

View in: PubMed
Wai KM, Saroj N, Boucher N, Aggarwal N, Ho AC, Rahimy E. Evaluating the Effect of Hypoglycemic Agents on Diabetic Retinopathy Progression. Ophthalmic Surg Lasers Imaging Retina. 2023 03; 54(3):158-165.

View in: PubMed
Rahimy E, Baker K, Thompson D, Saroj N. Impact of Systemic Dipeptidyl Peptidase-4 Inhibitor Use in Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2020 04 01; 51(4):226-234.

View in: PubMed
Pollack PS, Chadwick KD, Smith DM, Billger M, Hirshberg B, Iqbal N, Boulton DW. Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin. Cardiovasc Diabetol. 2017 09 13; 16(1):113.

View in: PubMed
Skolnik N, Jaffa FM, Kalyani RR, Johnson E, Shubrook JH. Reducing CV risk in diabetes: An ADA update. J Fam Pract. 2017 May; 66(5):300-308.

View in: PubMed
Heller S, Darp? B, Mitchell MI, Linnebjerg H, Leishman DJ, Mehrotra N, Zhu H, Koerner J, Fiszman ML, Balakrishnan S, Xiao S, Todaro TG, Hensley I, Guth BD, Michelson EL, Sager P. Considerations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: A report from the Cardiac Safety Research Consortium. Am Heart J. 2015 Jul; 170(1):23-35.

View in: PubMed
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015 Jan; 38(1):140-9.

View in: PubMed
Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014 Oct 28; 130(18):1579-88.

View in: PubMed
Williamson C, Glauser TA, Burton BS, Schneider D, Dubois AM, Patel D. Health care provider management of patients with type 2 diabetes mellitus: analysis of trends in attitudes and practices. Postgrad Med. 2014 May; 126(3):145-60.

View in: PubMed
Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin. 2007 Apr; 23(4):945-52.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement